PhRMA and BIO say Biden’s march-in proposal creates uncertainty in industry

PhRMA pres­i­dent Stephen Ubl ar­gued Thurs­day that the Biden ad­min­is­tra­tion’s new pro­pos­al on the use of march-in rights has “plant­ed the seeds of un­cer­tain­ty” around patent rights for pre­scrip­tion drugs.

Rep­re­sen­ta­tives from PhRMA and BIO, two of the largest biotech and phar­ma trade or­ga­ni­za­tions, con­demned the draft guid­ance dur­ing a me­dia call on Thurs­day, ar­gu­ing that the frame­work will harm in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.